People
Scientific luminary and MacArthur Fellowship winner Kevin Eggan, Ph.D. will lead early-stage research at rare disease-focused BioMarin.
The prize was awarded to Harvey J. Alter, Michael Houghton and Charles M. Rice for their efforts to identify the virus. Prior to their work, the medical world was only aware of Hepatitis A and B.
Pfizer CEO Albert Bourla responds to COVID-19 being brought into this week’s presidential debate with political terms, rather than scientific facts.
Merck announced that Roger M. Perlmutter, the company’s executive vice president and president of Merck Research Laboratories, was retiring effective January 1, 2021. He will be succeeded by Dean Y. Li.
At 74 years old, Trump is in a category of older Americans who are at more vulnerable to infection, and at higher risk of developing more serious symptoms.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Timothy Ray Brown, dubbed the “Berlin Patient,” the first ever to be cured of HIV, died from cancer on September 29.
The German company announced that the new CEO will take the reins in May 2021.
At a recent Demy-Colton Virtual Salon, Michael Gaito, head of healthcare investment banking at J.P. Morgan, discussed the strength of capital raises despite COVID-19 and the resilient state of the biotech sector in the run-up to the Presidential election in November and the virtual J.P. Morgan Healthcare Conference (and the virtual Biotech Showcase) in January, with Dennis Purcell, founder of Aisling Capital LLC.
The importance of diversity of patients in clinical studies cannot be overlooked, nor can the importance of diversity at the C-suite level. But, it’s equally important to have a diverse clinical research team as well.
PRESS RELEASES